Frattari, A.; Polilli, E.; Timelli, L.; Spagnuolo, F.; Fazii, P.; Parruti, G.
Monitoring Immune Dysfunction in Critically Ill Patients with Carbapenem-Resistant Acinetobacter baumannii Sepsis Treated with Regimens Including Cefiderocol: A Pilot Study to Identify Accessible Biomarkers to Stratify Patients’ Prognosis. Antibiotics 2024, 13, 1001.
https://doi.org/10.3390/antibiotics13111001
AMA Style
Frattari A, Polilli E, Timelli L, Spagnuolo F, Fazii P, Parruti G.
Monitoring Immune Dysfunction in Critically Ill Patients with Carbapenem-Resistant Acinetobacter baumannii Sepsis Treated with Regimens Including Cefiderocol: A Pilot Study to Identify Accessible Biomarkers to Stratify Patients’ Prognosis. Antibiotics. 2024; 13(11):1001.
https://doi.org/10.3390/antibiotics13111001
Chicago/Turabian Style
Frattari, Antonella, Ennio Polilli, Laura Timelli, Francesca Spagnuolo, Paolo Fazii, and Giustino Parruti.
2024. "Monitoring Immune Dysfunction in Critically Ill Patients with Carbapenem-Resistant Acinetobacter baumannii Sepsis Treated with Regimens Including Cefiderocol: A Pilot Study to Identify Accessible Biomarkers to Stratify Patients’ Prognosis" Antibiotics 13, no. 11: 1001.
https://doi.org/10.3390/antibiotics13111001
APA Style
Frattari, A., Polilli, E., Timelli, L., Spagnuolo, F., Fazii, P., & Parruti, G.
(2024). Monitoring Immune Dysfunction in Critically Ill Patients with Carbapenem-Resistant Acinetobacter baumannii Sepsis Treated with Regimens Including Cefiderocol: A Pilot Study to Identify Accessible Biomarkers to Stratify Patients’ Prognosis. Antibiotics, 13(11), 1001.
https://doi.org/10.3390/antibiotics13111001
